Merck
Merck Enters $2 Billion Agreement to Develop Lipoprotein(a) Inhibitor for Atherosclerosis Treatment
2025-03-26
Merck Launches $1 Billion Vaccine Facility in North Carolina, Boosting U.S. Manufacturing and Job Creation
2025-03-13
Merck’s Multi-Billion-Dollar KEYTRUDA Levels Up with Novel Subcutaneous Delivery, Matching IV Efficacy
2024-11-22
Merck’s KEYTRUDA Fails in Early-Stage Lung and Skin Cancer Trials, Ends Two Phase 3 Studies
2024-08-30
LATEST
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24